Methicillin resistant staphylococcus aureus natural history, complications and prognosis

Jump to navigation Jump to search

Methicillin resistant staphylococcus aureus infections Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Methicillin resistant staphylococcus aureus natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Methicillin resistant staphylococcus aureus natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Methicillin resistant staphylococcus aureus natural history, complications and prognosis

CDC on Methicillin resistant staphylococcus aureus natural history, complications and prognosis

Methicillin resistant staphylococcus aureus natural history, complications and prognosis in the news

Blogs on Methicillin resistant staphylococcus aureus natural history, complications and prognosis

Directions to Hospitals Treating Methicillin resistant staphylococcus aureus

Risk calculators and risk factors for Methicillin resistant staphylococcus aureus natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Complications

Complications of MRSA infection depends on the site of involvement:

Prognosis

MRSA in healthcare settings commonly causes serious and potentially life threatening infections, such as bloodstream infections, surgical site infections, or pneumonia.

It has been difficult to quantify the degree of morbidity and mortality attributable to MRSA. Patients with S. aureus infection had, on average, 3 times the length of hospital stay (14.3 vs 4.5 days), 3 times the total charges ($48,824 vs $14,141), and 5 times the risk of in-hospital death (11.2% vs 2.3%) than inpatients without this infection. Cosgrove et al, in a meta-analysis of 31 studies, conclude that bacteremia as a result of MRSA is associated with an increased mortality compared with MSSA bacteraemia with an odds ratio of 1.93 (95% CI, 1.54±2.42; In addition, Wyllie et al. report a death rate of 34% within 30 days among patients infected with MRSA, while among MSSA patients the death rate was similar at 27%.

The major issue is that there are a number of factors that can lead to someone's death, and it is believed that patients with MRSA bacteraemia are sicker and will consequently have a higher mortality because of their underlying illness. However, several studies including one by Blot and colleagues that have adjusted for underlying disease still found MRSA bacteraemia to have a higher attributable mortality than MSSA bacteraemia.[11]


References

Template:WH Template:WS